Beam Therapeutics BEAM Equity Issuance Costs In Accounts Payable And Accrued Expenses
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept beam:EquityIssuanceCostsInAccountsPayableAndAccruedExpenses.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Questions, answered.
- What is Beam Therapeutics's equity issuance costs in accounts payable and accrued expenses?
- Beam Therapeutics (BEAM) reported equity issuance costs in accounts payable and accrued expenses of $0 in Q1 2026.
- How has Beam Therapeutics's equity issuance costs in accounts payable and accrued expenses changed year-over-year?
- Beam Therapeutics's equity issuance costs in accounts payable and accrued expenses decreased by 100.0% year-over-year, from $641K to $0.